Literature DB >> 24552279

Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?

Reine El Omar1, Jacqueline Beroud, Jean-Francois Stoltz, Patrick Menu, Emilie Velot, Veronique Decot.   

Abstract

Due to their self-renewal capacity, multilineage differentiation potential, paracrine effects, and immunosuppressive properties, mesenchymal stromal cells (MSCs) are an attractive and promising tool for regenerative medicine. MSCs can be isolated from various tissues but despite their common immunophenotypic characteristics and functional properties, source-dependent differences in MSCs properties have recently emerged and lead to different clinical applications. Considered for a long time as a medical waste, umbilical cord appears these days as a promising source of MSCs. Several reports have shown that umbilical cord-derived MSCs are more primitive, proliferative, and immunosuppressive than their adult counterparts. In this review, we aim at synthesizing the differences between umbilical cord MSCs and MSCs from other sources (bone marrow, adipose tissue, periodontal ligament, dental pulp,…) with regard to their proliferation capacity, proteic and transcriptomic profiles, and their secretome involved in their regenerative, homing, and immunomodulatory capacities. Although umbilical cord MSCs are until now not particularly used as an MSC source in clinical practice, accumulating evidence shows that they may have a therapeutic advantage to treat several diseases, especially autoimmune and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24552279     DOI: 10.1089/ten.TEB.2013.0664

Source DB:  PubMed          Journal:  Tissue Eng Part B Rev        ISSN: 1937-3368            Impact factor:   6.389


  87 in total

1.  Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Authors:  Reine El Omar; Yu Xiong; Gabriel Dostert; Huguette Louis; Monique Gentils; Patrick Menu; Jean-François Stoltz; Émilie Velot; Véronique Decot
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

Review 2.  Upcycling umbilical cords: bridging regenerative medicine with neonatology.

Authors:  Alvaro Moreira; Yasmeen Alayli; Saloni Balgi; Caitlyn Winter; Samuel Kahlenberg; Shamimunisa Mustafa; Peter Hornsby
Journal:  J Matern Fetal Neonatal Med       Date:  2017-11-27

3.  Serum and xeno-free, chemically defined, no-plate-coating-based culture system for mesenchymal stromal cells from the umbilical cord.

Authors:  Xiaoyun Wu; Huiyan Kang; Xuemin Liu; Jin Gao; Kuijun Zhao; Zhijie Ma
Journal:  Cell Prolif       Date:  2016-08-04       Impact factor: 6.831

Review 4.  Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord.

Authors:  Melina Ramallo; Irene Carreras-Sánchez; Alba López-Fernández; Roberto Vélez; Màrius Aguirre; Sara Feldman; Joaquim Vives
Journal:  Histol Histopathol       Date:  2020-09-11       Impact factor: 2.303

5.  Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration.

Authors:  Maria Rosa Todeschi; Rania El Backly; Chiara Capelli; Antonio Daga; Eugenio Patrone; Martino Introna; Ranieri Cancedda; Maddalena Mastrogiacomo
Journal:  Stem Cells Dev       Date:  2015-03-18       Impact factor: 3.272

Review 6.  Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.

Authors:  Theresa L Whiteside
Journal:  Semin Immunol       Date:  2017-12-27       Impact factor: 11.130

7.  Umbilical cord mesenchymal stem cell (UC-MSC) transplantations for cerebral palsy.

Authors:  Huajiang Dong; Gang Li; Chongzhi Shang; Huijuan Yin; Yuechen Luo; Huipeng Meng; Xiaohong Li; Yali Wang; Ling Lin; Mingliang Zhao
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

8.  Impact of maternal and neonatal factors on umbilical cord CD34+ cells.

Authors:  Mohamed A Rowisha; Mohamed R El-Shanshory; Eslam E El-Hawary; Amira Youssef Ahmed; Shafeq Ryad Mustafa Altoraky
Journal:  Stem Cell Investig       Date:  2020-03-31

Review 9.  Response of vascular mesenchymal stem/progenitor cells to hyperlipidemia.

Authors:  Ting Chen; Yutao Wu; Wenduo Gu; Qingbo Xu
Journal:  Cell Mol Life Sci       Date:  2018-06-26       Impact factor: 9.261

10.  Direct Comparison of Wharton's Jelly and Bone Marrow-Derived Mesenchymal Stromal Cells to Enhance Engraftment of Cord Blood CD34(+) Transplants.

Authors:  Mark van der Garde; Melissa van Pel; Jose Eduardo Millán Rivero; Alice de Graaf-Dijkstra; Manon C Slot; Yoshiko Kleinveld; Suzanne M Watt; Helene Roelofs; Jaap Jan Zwaginga
Journal:  Stem Cells Dev       Date:  2015-10-08       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.